Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 28th International Conference on Cardiology and Healthcare Abu Dhabi, UAE.

Day 1 :

Keynote Forum

S Jamal Mustafa

West Virginia University, USA

Keynote: Coronary flow regulation and it’s signaling by adenosine

Time : 09:00-10:00

OMICS International Cardiology Care 2018 International Conference Keynote Speaker S Jamal Mustafa photo
Biography:

S Jamal Mustafa is a Professor of Pharmacology at West Virginia University School of Medicine and a Senior Advisor to the Pilot Core of the West Virginia Clinical Science and Translational Institute. He has served as an Assistant Dean for Research at the Health Sciences Center from 2005-15. He has received Dean’s
Award for Excellence in Research from School of Medicine in 2008 and became a Robert C Byrd Professor in 2010. In addition, he received Chancellor’s Award for Outstanding Achievement in Research and Scholarly Activities from Health Sciences Center in 2013. He had published over 200 manuscripts. For almost 40 years, he had been studying the role of adenosine receptors in coronary flow regulation and it is signaling in coronary smooth muscle and endothelial cells from various species including human. He and his teams past work has led to the approval of a selective A2A adenosine receptor agonist (Lexican®) for myocardial perfusion imaging. Currently he and his team are using adenosine receptor and beta-adrenergic receptor knockout mice to understand the relationship between these receptors in coronary flow regulation leading to treatment of coronary artery disease.

Abstract:

Adenosine acts through its receptors (A1, A2A, A2B and A3) via G-proteins and causes an increase in Coronary Flow (CF) mostly through A2A AR. However, the role of other ARs in the modulation of CF is not well understood. Using Knock Outs (KO), we investigated the role for each AR in the regulation of CF. Using the isolated heart from A3 KO mice; we reported an increase in A2A-mediated CF. Similarly, we found an increase in CF in A1 KO mice with A2A agonist (CGS- 21680; CGS). In addition, in A2A KO mice response to CGS was abolished, thus confirming the KO. On the other hand, A2A KO mice showed a decrease in CF to NECA (non-selective agonist). BAY60-6583 (A2B selective agonist; BAY) was without an effect on CF in A2B KO mice; however, it increased CF significantly in A2A KO. CGS also caused a significant increase in CF in A2B KO mice. In addition, exogenous adenosine-induced increase in CF in wild type, A2A KO and A2B KO mice were significantly reduced with catalase. BAY-induced increase in CF in WT was significantly inhibited with Glibenclamide. Overall, our data support stimulatory roles for A2A and A2B and inhibitory roles for A1 and A3 in the regulation of CF. These observations provide new evidence for the presence of all four ARs in CF regulation. We propose that, activation of A2A/B may release H2O2 which then activates KATP channels, leading to vasodilation. These studies may lead to the better understanding of the role of ARs in coronary disease and better therapeutic approaches.

Keynote Forum

Brajesh Mittal

Garhoud Private Hospital, UAE

Keynote: Stent blockage: Different shades of grey

Time : 10:00-11:00

OMICS International Cardiology Care 2018 International Conference Keynote Speaker Brajesh Mittal photo
Biography:

Currently Brajesh Mittal is working as Consultant Interventional Cardiologist and Head of Cardiology Department at Garhoud Private Hospital, Dubai. He is the Chairman of SCALE- “Stemi Care for All in Emirates” and CME Committee and Garhoud Hospital. His main area of interest is complex coronary and primary angioplasty. He has several publications and presentations at national and international level and is a regular participant as Faculty at large forums incl. European Society of Hypertension, Euro PCR, Arab Health, Emirates Cardiac Society, National Interventional Council India and Cardiology Society of India

Abstract:

Stent blockage has and estimated incidence of 1-5%. It is multifactorial nature and may have devastating consequences viz. AC myocardial infarction/sudden cardiac death, case fatality rate can be as high as 45%. It is prudent to identify those at high risk and should have a clear aim to minimize occurrence. There are several predictors of stent thrombosis and are related to 3 groups: patient, lesion and procedure. Among the most important ones are antiplatelet non-responsiveness, noncompliance or premature cessation. Long lesions/small vessels; stent under expansion. Strongest factors are: Discontinuation OR Dual Antiplatelet Therapy (DAPT), stent under sizing, intermediate lesion proximal to stent, concomitant malignancy, and acute coronary syndrome. Overall early ST >>late ST (>70%). Drug eluting stents also carry the risk of more frequent Very Late Stent Thrombosis (VLST). Underlying pathology depends upon the timing of stent occlusion; while acute and subacute stent occlusion is predominantly thrombotic, later occlusions are more of neo-atherosclerosis. A good mix is being underlying neo-atherosclerosis, thin cap fibroatheroma and thrombus on top. DAPT compliance and procedural optimization are the two most important areas of attention for all the interventional cardiologists to minimize and avoid this potentially devastating complication.